New hope for rare bleeding disorder: experimental drug aims to stop bleeding episodes
NCT ID NCT07136857
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 28 times
Summary
This study tests an investigational drug called eptacog beta for people with Glanzmann thrombasthenia, a rare inherited bleeding disorder. Over 9 months, about 6 participants will use the drug to treat serious bleeding episodes, with an optional extension to see if regular infusions can prevent future bleeds. The goal is to see if the drug is safe and effective for controlling bleeding.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLANZMANN THROMBASTHENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arthur M. Blank Hospital | Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30329, United States
Conditions
Explore the condition pages connected to this study.